{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreid5ynjwx745sbxvghoybgqcncdzwwg56hdhzfxmmlyprxjrt7zsvu",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3meyghypwgpn2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiapwkhhfqgjzyrg5gfdejrjftninxrbxfkedbpzzdbquvyl7nzire"
    },
    "mimeType": "image/jpeg",
    "size": 124790
  },
  "path": "/news/2026-02-fda-drug-proof-patent-violation.html",
  "publishedAt": "2026-02-16T10:04:34.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Medical economics"
  ],
  "textContent": "Federal law requires every prescription drug to include a document describing dosing guidelines, contraindications, results from clinical trials and safety considerations. But a spate of recent court decisions has problematically treated that safety information in a drug's legally required package insert as key evidence in high-stakes patent cases against generic-drug manufacturers.",
  "title": "Research: FDA drug labels not proof of patent violation"
}